Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 10/20 | 0.43 |
| ▸ | NOTCH3 | Q9UM47 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | RBPJ | Q06330 | 3/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030708 | 0.89 | NOTCH1 (0.42) | NOTCH1NOTCH3LMNARBPJ | |
| SCHEMBL17030687 | 0.88 | NOTCH1 (0.42) | NOTCH1NOTCH3LMNAMEN1ALB | |
| SCHEMBL15622047 | 0.86 | NOTCH1 (0.45) | NOTCH1NOTCH3LMNAMEN1ALB | |
| SCHEMBL22455443 | 0.86 | NOTCH1 (0.45) | NOTCH1NOTCH3LMNAMEN1ALB | |
| SCHEMBL15622200 | 0.86 | NOTCH1 (0.45) | NOTCH1NOTCH3LMNAMEN1ALB | |
| SCHEMBL29692154 | 0.86 | NOTCH1 (0.45) | NOTCH1NOTCH3LMNAMEN1ALB | |
| SCHEMBL15622296 | 0.86 | NOTCH1 (0.47) | NOTCH1NOTCH3CCKBRRBPJ | |
| SCHEMBL15629462 | 0.86 | NOTCH1 (0.54) | NOTCH1NOTCH3LMNAMEN1ALB | |
| SCHEMBL17019559 | 0.86 | NOTCH1 (0.47) | NOTCH1NOTCH3CCKBRRBPJ | |
| SCHEMBL15622551 | 0.86 | NOTCH1 (0.54) | NOTCH1NOTCH3LMNAMEN1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897947-B1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9242941-B2 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-METERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, NR1I3 | NOTCH1 61/4885NOTCH3 34/4885LMNA 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.